相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial
Ralf Trappe et al.
LANCET ONCOLOGY (2012)
Epstein-Barr Virus-Related Post-Transplant Lymphoproliferative Disorders: Pathogenetic Insights for Targeted Therapy
J. P. Nourse et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2011)
Pre-emptive rituximab based on viraemia and T cell reconstitution: a highly effective strategy for the prevention of Epstein-Barr virus-associated lymphoproliferative disease following stem cell transplantation
Austen Worth et al.
BRITISH JOURNAL OF HAEMATOLOGY (2011)
Spectrum of Cancer Risk Among US Solid Organ Transplant Recipients
Eric A. Engels et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2011)
Malignancy after heart transplantation:: Incidence, prognosis and risk factors
M. G. Crespo-Leiro et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2008)
Evaluation of the Epstein-Barr virus R-gene quantification kit in whole blood with different extraction methods and PCR platforms
Samira Fafi-Kremer et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2008)
Monitoring of human cytomegalovirus infection in immunosuppressed patients using real-time PCR on whole blood
C. Deback et al.
JOURNAL OF CLINICAL VIROLOGY (2007)
Prospective phase II trial of extended treatment with rituximab in patients with B-cell post-transplant lymphoproliferative disease
Eva Gonzalez-Barca et al.
HAEMATOLOGICA (2007)
Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial
Tanzina Haque et al.
BLOOD (2007)
Adolescents are more likely to develop posttransplant lymphoproliferative disorder after primary Epstein-Barr virus infection than younger renal transplant recipients
Jodi M. Smith et al.
TRANSPLANTATION (2007)
Effect of cytomegalovirus prophylaxis with immunoglobulin or with antiviral drugs on post-transplant non-Hodgkin lymphoma:: a multicentre retrospective analysis
Gerhard Opelz et al.
LANCET ONCOLOGY (2007)
Epstein-Barr virus-DNA load monitoring late after lung transplantation: A surrogate marker of the degree of immunosuppression and a safe guide to reduce immunosuppression
Nicolaas A. Bakker et al.
TRANSPLANTATION (2007)
CHOP-21 for the treatment of post-transplant lymphoproliferative disorders following solid organ transplantation
Sylvain Choquet et al.
HAEMATOLOGICA (2007)
Treatment of solid organ transplant recipients with autologolus Epstein Barr virus-specific cytotoxic T lymphocytes (CTLs)
Barbara Savoldo et al.
BLOOD (2006)
CMV-IVIG for prevention of Epstein Barr virus disease and posttransplant lymphoproliferative disease in pediatric liver transplant recipients
M. Green et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2006)
Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders:: results of a prospective multicenter phase 2 study
S Choquet et al.
BLOOD (2006)
A randomized trial of ganciclovir versus ganciclovir plus immune globulin for prophylaxis against Epstein-Barr virus related posttransplant lymphoproliferative disorder
A Humar et al.
TRANSPLANTATION (2006)
Effect of anti-CD 20 antibody rituximab in patients with post-transplant lymphoproliferative disorder (PTLD)
SHK Oertel et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2005)
Ganciclovir and acyclovir reduce the risk of post-transplant lymphoproliferative disorder in renal transplant recipients
DP Funch et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2005)
Revision of the 1990 working formulation for the standardization of nomenclature in the diagnosis of heart rejection
S Stewart et al.
JOURNAL OF HEART AND LUNG TRANSPLANTATION (2005)
Quantitative EBV viral loads and immunosuppression alterations can decrease PTLD incidence in pediatric liver transplant recipients
TC Lee et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2005)
Assessment of automated DNA extraction coupled with real-time PCR for measuring Epstein-Barr virus load in whole blood, peripheral mononuclear cells and plasma
S Fafi-Kremer et al.
JOURNAL OF CLINICAL VIROLOGY (2004)
Prompt versus preemptive intervention for EBV lymphoproliferative disease
HJ Wagner et al.
BLOOD (2004)
Association of the type of induction immunosuppression with posttransplant lymphoproliferative disorder, graft survival, and patient survival after primary kidney transplantation
WS Cherikh et al.
TRANSPLANTATION (2003)
Autologous Epstein-Barr virus (EBV)-specific cytotoxic T cells for the treatment of persistent active EBV infection
B Savoldo et al.
BLOOD (2002)
Longitudinal analysis of Epstein-Barr viral load in plasma and peripheral blood mononuclear cells of transplanted patients by real-time polymerase chain reaction
HJ Wagner et al.
TRANSPLANTATION (2002)
Prevention of Epstein-Barr virus-lymphoproliferative disease by molecular monitoring and preemptive rituximab in high-risk patients after allogeneic stem cell transplantation
JWJ van Esser et al.
BLOOD (2002)
Infusion of autologous Epstein-Barr virus (EBV) -: specific cytotoxic T cells for prevention of EBV-related lymphoproliferative disorder in solid organ transplant recipients with evidence of active virus replication
P Comoli et al.
BLOOD (2002)
Routine use of real-time quantitative PCR for laboratory diagnosis of Epstein-Barr virus infections
K Brengel-Pesce et al.
JOURNAL OF MEDICAL VIROLOGY (2002)
Epstein-Barr virus (EBV) reactivation is a frequent event after allogeneic stem cell transplantation (SCT) and quantitatively predicts EBV-lymphoproliferative disease following T-cell-depleted SCT
JWJ van Esser et al.
BLOOD (2001)
Frequent monitoring of Epstein-Barr virus DNA load in unfractionated whole blood is essential for early detection of posttransplant lymphoproliferative disease in high-risk patients
SJC Stevens et al.
BLOOD (2001)
The role of EBV in post-transplant malignancies: a review
P Hopwood et al.
JOURNAL OF CLINICAL PATHOLOGY (2000)